Advertisement

PharmacoEconomics & Outcomes News

, Volume 818, Issue 1, pp 5–5 | Cite as

Alemtuzumab preferred treatment option in relapsing MS

Clinical study
  • 11 Downloads

Reference

  1. Chirikov V, et al. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States. Value in Health : 6 Dec 2018. Available from: URL: https://doi.org/10.1016/j.jval.2018.08.011

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations